Arrowhead Pharmaceuticals (ARWR) Return on Capital Employed: 2011-2025
Historic Return on Capital Employed for Arrowhead Pharmaceuticals (ARWR) over the last 14 years, with Sep 2025 value amounting to 0.08%.
- Arrowhead Pharmaceuticals' Return on Capital Employed rose 74.00% to 0.08% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.08%, marking a year-over-year increase of 74.00%. This contributed to the annual value of 0.09% for FY2025, which is 80.00% up from last year.
- Per Arrowhead Pharmaceuticals' latest filing, its Return on Capital Employed stood at 0.08% for Q3 2025, which was up 198.38% from -0.08% recorded in Q2 2025.
- Arrowhead Pharmaceuticals' Return on Capital Employed's 5-year high stood at 0.08% during Q3 2025, with a 5-year trough of -0.67% in Q2 2024.
- Moreover, its 3-year median value for Return on Capital Employed was -0.30% (2023), whereas its average is -0.36%.
- As far as peak fluctuations go, Arrowhead Pharmaceuticals' Return on Capital Employed plummeted by 47bps in 2024, and later spiked by 74bps in 2025.
- Quarterly analysis of 5 years shows Arrowhead Pharmaceuticals' Return on Capital Employed stood at -0.35% in 2021, then grew by 12bps to -0.23% in 2022, then dropped by 24bps to -0.47% in 2023, then declined by 16bps to -0.64% in 2024, then spiked by 74bps to 0.08% in 2025.
- Its last three reported values are 0.08% in Q3 2025, -0.08% for Q2 2025, and -0.11% during Q1 2025.